Home > Insider Trading > Filing (0001209191-14-067908)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1512762	Coherus Biosciences Inc.	CHRS	Biological Products, (No Disgnostic Substances) (2836)	273615821

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1245624	James Healy	C/O Coherus Biosciences, Inc. 201 Redwood Shores Parkway, Suite 200 Redwood City CA 94065		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2014-11-12	47	$0.00	47	No	4	C	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2014-11-12	1,846,890	$0.00	1,981,863	No	4	C	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Acquisiton	2014-11-12	149,970	$0.00	2,131,833	No	4	C	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Acquisiton	2014-11-12	425,926	$13.50	2,557,759	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2014-11-12	47	$0.00	47	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-11-12	1,846,890	$0.00	1,846,890	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-11-12	149,970	$0.00	149,970	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis upon the closing of Issuer's initial public offering.
The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners VII, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners VII, L.P.
Sofinnova Venture Partners VII, L.P. purchased an additional 425,926 shares of Issuer's Common Stock in connection with the IPO at the offering price of $13.50 per share.
The Series B Preferred Stock and Series C Preferred Stock have no expiration date.